Role of repetitive transcranial magnetic stimulation (rTMS) in migraine prophylaxis a randomized control trial

Phase 4

Recruiting

Conditions: Patients of Migraine headache of more than 15 years age. No history of focal neurological deficit, no associated comorbidities like uncontrol hypertension, renal failure, pregnancy, lactation

Registration Number: CTRI/2012/04/002545

Lead Sponsor: Sanjay Gandhi Postgraduate Institute of Medical Sciences

Brief Summary: Headache is one of the most common neurological disorders seen in the outpatient department in our institute. On an average, two of ten patients evaluated by a neurologist in the outpatient department, have migraine. The disease has disabling potential, with the greatest impact on public health. The goals of migraine preventive therapy are to: (1) reduce attack frequency, severity, and duration; (2) improve responsiveness to treatment of acute attacks; and (3) improve function and reduce disability. Prophylaxis for migraine includes various classes of drugs alpha-2 agonist, antiepileptics, antidepressants, SSRIs, monoamine oxidase inhibitors, beta blockers, calcium channel blockers. rTMS has been reported to have beneficial effects in migraine with aura and rTMS has shown to be beneficial in reducing migraine frequency in some studies. This prospective randomized control study will investigate the efficacy and safety of rTMS in comparison with sham stimulation in the prophylactic treatment of migraine headache.

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: All

Target Recruitment: 100

Inclusion Criteria

Patients of migraine headache with frequency of attacks more than four attcaks per month.

Exclusion Criteria

Pregnancy, liver or kidney diseases, malignancy, severe hypertension, pacemaker or metallic implants and history of seizure or structural brain lesions.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. More than 50% improvement in frequency of headache	1 month
2. Global improvement in VAS	1 month

Secondary Outcome Measures

Name	Time	Method
Severity of headache, Functional improvement, rescue analgesic intake and somatosensory evoked potential before and after rTMS in selected patients	1 month

Trial Locations

Locations (1): Sanjay Gandhi Postgraduate Institute of Medical Sciences
🇮🇳
Lucknow, UTTAR PRADESH, India
Sanjay Gandhi Postgraduate Institute of Medical Sciences
🇮🇳Lucknow, UTTAR PRADESH, India
Dr U K Misra Dept of Neurology Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow UP
Principal investigator
05222494167
drukmisra@rediffmail.com